Boron-containing medicine and preparation method thereof
Developing new boron-containing drugs through the polymerization reaction of dopamine and its derivatives with boron-containing compounds has solved the problems of low tumor targeting and utilization in the existing technology, significantly improved the boron concentration and therapeutic effect in tumors, and expanded the Indications, including the treatment of brain tumors.
Patent Information
- Application Number
- CN202310131163.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-17
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-02-17
AI Technical Summary
The existing boron-containing drugs have low tumor targeting and utilization, resulting in large clinical dosage, high treatment cost and safety risks, and are difficult to accurately target tumors, increasing the risk of damage to normal tissues.
Develop a new boron-containing drug through the polymerization of dopamine and its derivatives with boron-containing compounds to improve tumor targeting and utilization, and use specific preparation methods and indications to expand its application.
It significantly improves the boron concentration in the tumor and the boron concentration ratio of the tumor/normal tissue, extends the retention time of the drug in the tumor, reduces the dosage and side effects, improves the treatment effect, and expands indications, including brain tumors treat.
Smart Images

Figure CN116077655B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of tumor therapeutic drugs, and in particular relates to a boron-containing drug and a preparation method thereof. Background Art
[0002] At present, there are two boron-containing drugs that have been used in clinical practice, namely 4-borylphenylalanine (BPA) and sodium mercaptoundecahydrocloso-dodecaborate (BSH). At present, a small number of clinical trials have been carried out on drugs based on BSH, but they have not yet been formally approved for marketing. BSH is popular among researchers because of its high boron-10 content, but due to the difficulty in the synthesis and purification process of raw materials, its source is limited and expensive. In addition, the clinical safety and effectiveness of BSH have not been fully certified, and research based on BSH is currently decreasing. BPA has received more attention in recent years because of its relatively simple synthesis and purification process, good compound stability, and more sufficient research and certification of safety and effectiveness in clinical application.
[0003] Currently, BPA-based drug preparations are mainly made into solution preparations or lyophilized powders using BPA as the raw material. The main problems are low tumor uptake rate and rapid blood clearance, which makes the clinical dosage of such drug preparations extremely large. The main challenge facing boron-containing drugs is how to improve their tumor targeting and utilization rate.
[0004] When boron neutron capture therapy is used clinically to treat tumors, 10 The concentration of BPA needs to be maintained at about 30µg / g during neutron irradiation to achieve a good therapeutic effect. The tumor / normal tissue concentration ratio (T / N ratio) of BPA can only reach 3:1. When the BPA level in cancer cells increases, it will be excreted through the "anti-transport" mechanism. The currently approved BPA-based solution preparation Steboronine® is used to maintain the local tumor concentration during treatment. 10 B concentration, before treatment, adult patients need to be intravenously infused with borophalan at a rate of 200 mg / kg per hour ( 10 B) 2 hours. During treatment, adult patients need to receive an intravenous drip of borophalan at a rate of 100 mg / kg per hour. 10B) 30-60min. Due to its poor tumor targeting or low T / N ratio and rapid metabolism, a 60kg patient needs 36g of BPA for one treatment. The high clinical dosage not only increases the cost of treatment, but also increases the safety risk. Furthermore, the tumor targeting or low T / N ratio makes the drug have higher requirements on the accuracy of neutron source irradiation in clinical applications, and also increases the risk of excessive irradiation dose to normal tissue (if irradiating normal tissue, due to the low T / N ratio, the boron content of normal tissue is high, and normal tissue is also easily damaged). Further, the clinical application and expansion of indications of the drug are limited.
[0005] In view of this, the present invention is proposed. Summary of the invention
[0006] In order to solve the technical problems in the background technology, one purpose of the present invention is to develop a safe and effective boron-containing pharmaceutical preparation with better tumor targeting and higher utilization rate based on dopamine and its derivatives and boron-containing compounds, develop a preparation method of such a boron-containing drug and study its potential application in the treatment of diseases such as tumors. Such a boron-containing pharmaceutical preparation can significantly reduce the dosage of the boron-containing drug on the basis of safety and effectiveness, and further expand more indications on the basis of good tumor targeting distribution.
[0007] To achieve the above object, the first technical solution adopted by the present invention is:
[0008] Boron-containing drugs are obtained by polymerization reaction of dopamine and its derivatives with boron-containing compounds.
[0009] Preferably, the boron-containing compound includes, but is not limited to, any one or more of boric acid, boric acid phenylalanine and its derivatives, boric acid proline, boric acid aspartic acid, boric acid tyrosine, boric acid cysteine, boric acid methionine, boric acid serine, 5-amino-2,3-difluorophenylboric acid, 3-amino-5-cyanophenylboric acid, 3-amino-4-methylphenylboric acid, 3-aminophenylboronic acid hydrochloride, and 4-carbamoylphenylboric acid.
[0010] Preferably, the boron-containing compound comprises any one of boric acid phenylalanine and its derivatives.
[0011] Preferably, the boric acid phenylalanine and its derivatives are 4-boronic acid-L-phenylalanine (BPA).
[0012] Preferably, the dopamine and its derivatives include any one or more of dopamine, 4-(2-aminopropyl)benzene-1,2-diol, norepinephrine (1-(3,4-dihydroxyphenyl)-2-aminoethanol), levomethyldopa (2-methyl-3-(3,4-dihydroxyphenyl)-L-alanine), droxidopa ((2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic acid), and 5-hydroxydopamine; preferably dopamine, levomethyldopa (2-methyl-3-(3,4-dihydroxyphenyl)-L-alanine) or 5-hydroxydopamine.
[0013] Preferably, the mass ratio of the dopamine and its derivatives to the boron-containing compound is (1-10):1.
[0014] Preferably, the mass ratio of the dopamine and its derivatives to the boron-containing compound is (3-4):1.
[0015] Preferably, the boron content in the boron-containing drug is 0.1% to 1.0%.
[0016] Preferably, the indications of the boron-containing drug include head and neck tumors, lung cancer, peritoneal cancer, hepatocellular carcinoma, gastric cancer, melanoma, pancreatic cancer, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, breast cancer, colon cancer, colorectal cancer, uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, vulvar cancer, thyroid cancer, B-cell lymphoma or leukemia and the like; preferably, the indications are head and neck tumors, melanoma or glioma.
[0017] The second technical solution adopted by the present invention is:
[0018] A method for preparing a boron-containing drug comprises the following steps:
[0019] The aqueous solution of dopamine and its derivatives is mixed with the aqueous solution of boron-containing compounds for reaction, and the solid-liquid separation is performed to obtain a solid, which is then washed and freeze-dried to obtain the product.
[0020] Preferably, the pH of the mixed reaction is 6-14.
[0021] Preferably, the pH of the mixed reaction is 8-11.
[0022] Preferably, the mixing reaction time is 0.5 to 48 hours, and the stirring speed during the reaction is above 200 rpm.
[0023] Compared with the prior art, the present invention has the following beneficial effects:
[0024] 1. The concentration of the boron-containing drug prepared by the present invention in the tumor is as high as 70 μg / g, and the boron concentration ratio of the tumor and the blood is significantly improved, which can reach 70:1, which is much higher than the tumor / normal tissue boron concentration ratio of the current BPA drug preparation, greatly improving the tumor uptake rate, significantly improving the enrichment of boron in the tumor, improving the efficacy, and being able to be quickly cleared in the blood and normal organs, which can significantly reduce the dosage of the drug and reduce the side effects, thereby having better tumor targeting and higher utilization rate, and significantly improving the therapeutic effect of the tumor.
[0025] 2. The drug of the present invention has the characteristics of being retained in tumor tissue for a long time and having a long treatment window period, which overcomes the disadvantage of the prior art that continuous infusion is required during boron neutron irradiation. Experiments on subcutaneous glioma in mice show that when the dosage is 150 mg / kg, the boron concentration is within the range of 24 to 36 hours, the boron concentration can be maintained above 30 µg / g, the treatment window period exceeds 12 hours, and there is no need for continuous infusion of boron-containing drugs during the treatment process, making the treatment process easier to implement.
[0026] 3. Ordinary nano drugs cannot pass through the blood-brain barrier and thus cannot usually be used to treat brain tumors. However, the boron-containing drug of the present invention can pass through the blood-brain barrier and be enriched in gliomas, and the drug can be maintained above the therapeutic concentration for a long time, making it possible to use it to treat brain tumors.
[0027] 4. The boron-containing drug of the present invention has low toxicity and good biocompatibility.
[0028] 5. The boron-containing drug of the present invention has the characteristic of generating heat under near-infrared light irradiation, that is, it has photothermal properties. The photothermal conversion efficiency of the boron-containing drug is 39.46%, which can realize boron neutron and photothermal combined therapy. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 is the Fourier transform infrared (FT-IR) spectrum of the boron-containing drug in Example 1;
[0030] Figure 2 This is the particle size distribution diagram of the boron-containing drug in Example 1;
[0031] Figure 3 is a SEM image of the boron-containing drug in Example 2;
[0032] Figure 4 The cell survival rates at 24h, 48h and 72h were obtained by using three sialic acid-high-expressing tumor cell lines HepG2, SKOV3 and H22 to detect the toxicity of boron-containing drugs in Example 3;
[0033] Figure 5This is the in vivo distribution experiment of boron-containing drugs in subcutaneous brain glioma models in mice in Example 4, and the distribution diagram of boron in mice at 12h, 24h and 36h after administration;
[0034] Figure 6 This is the in vivo distribution experiment of the boron-containing drug in the mouse orthotopic brain glioma model in Example 5, and the distribution diagram of boron in the mouse body 24 hours after administration;
[0035] Figure 7 is a SEM image of the boron-containing drug in Example 8;
[0036] Figure 8 The boron-containing drug in Example 13 is subjected to a power density of 1.5 W / cm 2 Temperature rise curve of boron-containing drugs under 808 nm near-infrared laser irradiation. DETAILED DESCRIPTION
[0037] In order to better understand the technical solution of the present invention, the technical solution of the present invention will be further described below in conjunction with the accompanying drawings and embodiments. The mode for implementing the present invention includes but is not limited to the following embodiments, which are used to illustrate the present invention but are not used to limit the scope of protection of the present invention. Unless otherwise specified, the technical means used in the embodiments are conventional means well known to those skilled in the art. The test methods in the following embodiments, unless otherwise specified, are conventional methods.
[0038] The first embodiment of the present invention provides a boron-containing drug, which is obtained by polymerization reaction of dopamine and its derivatives with a boron-containing compound.
[0039] The particle size of the boron-containing drug in this embodiment is between 50-1000 nanometers, and the boron-containing drug can enter cells and pass through the blood-brain barrier.
[0040] This implementation method mainly improves the targeting characteristics of boron-containing drugs in the body by optimizing the composition and structure, thereby increasing the T / N ratio of tumors and normal tissues, prolonging the retention time of drugs in tumors, and enabling faster metabolism from blood and normal tissues and organs, thereby reducing the dosage of boron-containing drugs and reducing safety risks during treatment, thereby having better tumor targeting and higher utilization rate, and significantly improving the therapeutic effect of tumors. It improves the therapeutic effect of boron-containing drugs and obtains the expansion of indications, while significantly reducing the cost of drug treatment.
[0041] The boron-containing drug of this embodiment can enter the cell through endocytosis, but the tumor cell cannot expel it through the anti-transport mechanism, which prolongs the retention time in the tumor cell, solves the problem of large BPA dosage in boron neutron capture therapy, and further improves the enrichment of boron-containing drugs in tumor lesions, thereby improving the treatment effect. The distribution experiment of subcutaneous brain glioma in mice showed that when the dosage was 150 mg / kg, the boron concentration could be maintained above 30 µg / g within the range of 24 to 36 hours, and the treatment window period exceeded 12 hours. There was no need for continuous infusion of boron-containing drugs during the treatment process, which brought great convenience to the treatment of patients.
[0042] The boron-containing drug of this embodiment is used for diseases such as head and neck tumors, lung cancer, peritoneal cancer, hepatocellular carcinoma, gastric cancer, melanoma, pancreatic cancer, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, breast cancer, colon cancer, colorectal cancer, uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, vulvar cancer, thyroid cancer, B-cell lymphoma or leukemia; preferably, head and neck tumors, melanoma or glioma.
[0043] The boron-containing drug can be metabolized in the body (biodegradable), and its drug concentration decreases rapidly 48 hours after injection into the body until it is completely metabolized and cleared.
[0044] The boron-containing drug can generate heat under near-infrared light irradiation, has strong near-infrared absorption and high photothermal conversion efficiency. The photothermal conversion efficiency of 0.1 mg / mL of boron-containing drug irradiated with near-infrared light with a wavelength of 808 nm is about 39%, which can realize boron neutron therapy and photothermal combined therapy.
[0045] Regarding the selection of raw material components, the boron-containing compound includes, but is not limited to, any one or more of boric acid, boric acid phenylalanine and its derivatives, boric acid proline, boric acid aspartic acid, boric acid tyrosine, boric acid cysteine, boric acid methionine, boric acid serine, 5-amino-2,3-difluorophenylboric acid, 3-amino-5-cyanophenylboric acid, 3-amino-4-methylphenylboric acid, 3-aminophenylboronic acid hydrochloride, and 4-carbamoylphenylboronic acid. Preferably, any one of boric acid phenylalanine and its derivatives is included; more preferably, boric acid 4-boronic acid-L-phenylalanine (BPA).
[0046] The dopamine and its derivatives include any one or more of dopamine, 4-(2-aminopropyl)benzene-1,2-diol, norepinephrine (1-(3,4-dihydroxyphenyl)-2-aminoethanol), levomethyldopa (2-methyl-3-(3,4-dihydroxyphenyl)-L-alanine), droxidopa ((2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic acid), and 5-hydroxydopamine; preferably dopamine, levomethyldopa (2-methyl-3-(3,4-dihydroxyphenyl)-L-alanine) or 5-hydroxydopamine.
[0047] Regarding the usage of the raw material components, the mass ratio of the dopamine and its derivatives to the boron-containing compound is (1-10):1, preferably (3-4):1.
[0048] The boron content in the boron-containing medicine is 0.1% to 1.0%.
[0049] The second embodiment of the present invention provides a method for preparing a boron-containing drug, comprising mixing an aqueous solution of dopamine and its derivatives with an aqueous solution of a boron-containing compound for reaction, separating the solid from the liquid to obtain a solid, and washing and freeze-drying the solid.
[0050] The pH of the mixed reaction is 6 to 14, preferably 8 to 11. The mixed reaction time is 0.5 to 48 hours, and the stirring speed during the reaction is above 200 rpm.
[0051] The solvent for the mixed reaction is not particularly limited, and the reaction can be carried out directly in an aqueous solution, or in methanol, ethanol, acetone, DMF, THF or any mixed solution thereof.
[0052] The boron-containing drug of the present invention has good resolubility after freeze-drying, and the resolubility agent includes but is not limited to one of sterile water for injection, sodium chloride injection, glucose injection, and PBS buffer solution.
[0053] The boron-containing drugs and their properties are described below through a number of specific examples.
[0054] Example 1 Preparation of Boron-Containing Drugs
[0055] (1) Weigh 80 mg of dopamine hydrochloride into a reaction bottle, add 34 mL of 30% ethanol solution, and stir to dissolve;
[0056] (2) Weigh 20 mg of BPA into a centrifuge tube, add 3 mL of water, and then add 0.2 mL of 2.5 mol / L NaOH solution until BPA is completely dissolved;
[0057] (3) Add the solution in (2) to (1), adjust the pH to about 10 with NaOH, and stir at 300 rpm for 24 h;
[0058] (4) Centrifuge at 10,000 rpm for 10 min and wash with pure water three times;
[0059] (5) The product was suspended in 6 mL of water and freeze-dried to obtain the boron-containing drug.
[0060] The infrared spectrum of the boron-containing drug prepared in this example is as follows Figure 1 As shown, boron-containing drugs have an infrared absorption band of BN bond at 1388 cm -1 The particle size distribution is as follows Figure 2 As shown, the average particle size is 191.8 nm.
[0061] Example 2 Redissolution experiment of boron-containing drugs after freeze-drying
[0062] Take 5 mg of the boron-containing drug in Example 1, add 5 mL of solvent, the solvent includes but is not limited to any one of sterile water for injection, sodium chloride injection, glucose injection, PBS buffer, and water as a dispersant, mix manually and then perform SEM detection. The morphology is shown in Figure 3 It is spherical.
[0063] Example 3 In vitro cytotoxicity evaluation of boron-containing drugs for 24 to 72 hours
[0064] The evaluation time was 24 to 72 hours, and the detection method was Cell Counting Kit-8 (CCK8), a rapid and highly sensitive detection kit for cell proliferation and cytotoxicity, using three sialic acid-high-expressing tumor cell lines HepG2, SKOV3 and H22 for detection.
[0065] The specific operation steps are as follows: (1) HepG2, SKOV3 and H22 cells with good growth status were prepared into a certain concentration (5×10 3 Cells / 100uL) of cell suspension were added to each well of a 96-well cell culture plate at 100uL.
[0066] (2) 10 uL of the boron-containing drug of Example 1 was added to the culture wells at 0, 10, 20, 50, 100, 200 and 500 µg / mL, respectively, and the culture was continued in a 37°C incubator for a certain period of time;
[0067] (3) Samples were taken at 24h, 48h and 72h, and the absorbance was measured at a wavelength of 450nm to calculate the cell survival rate. At 72h, the cell survival rate was above 80%, indicating that the cytotoxicity of boron-containing drugs was very low. The specific results are shown in Figure 4 .
[0068] Example 4 In vivo distribution experiment of boron-containing drugs in subcutaneous brain glioma model of mice
[0069] The boron-containing drug of Example 1 was injected into tumor-bearing mice via the tail vein at a dose of 150 mg / kg. At 12h, 24h and 36h after administration, normal tissues of the heart, liver, spleen, lung, kidney, blood, brain, tumor and tumor margin were taken from the mice, and each tissue was weighed and digested. The boron concentration in each organ was measured by ICP-MS. At 24h, the boron concentration in the tumor site reached 74μg / g, and the T / N ratio was as high as 70:1. The distribution of boron in mice at 12h, 24h and 36h after administration is shown in Figure 1. Figure 5 , as shown in Table 1.
[0070] Table 1 Distribution of boron in mice 12h, 24h and 36h after administration
[0071] .
[0072] This example studies the distribution of subcutaneous brain glioma model animals. The mice were injected with a tail vein at a dose of 150 mg / kg of boron-containing drugs. At 12h, 24h and 36h after administration, the heart, liver, spleen, lung, kidney, blood, brain, tumor, and normal tissues at the edge of the tumor were taken from the mice, and the boron concentration in each organ was measured by ICP-MS. The boron concentration in the tumor reached a maximum of 74µg / g at 24h, and it could be maintained at more than 30µg / g at 36h. The treatment window period exceeded 12h. There was no need for continuous infusion of boron-containing drugs during the treatment process, and the T / N ratio could reach 70:1 (Table 1). The damage to normal tissues during the boron neutron capture therapy was minimal.
[0073] Example 5 In vivo distribution experiment of boron-containing drugs in an orthotopic brain glioma model in mice
[0074] The boron-containing drug of Example 1 was injected into tumor-bearing mice via the tail vein at a dose of 100 mg / kg. 24 hours after administration, the heart, liver, spleen, lung, kidney, blood, right brain tumor site, right brain non-tumor site, and left brain of the mice were taken, and each tissue was weighed and digested. The boron concentration in each organ was measured by ICP-MS. The boron concentration in the tumor site was above 30 μg / g, and the T / N ratio was greater than 7:1. The distribution of boron in the mice 24 hours after administration is as follows: Figure 6 , as shown in Table 2.
[0075] Table 2 Distribution of boron in mice 24 hours after administration
[0076] .
[0077] It can be seen from the experimental results in Tables 1 and 2 that the boron-containing drug prepared by the present invention is highly absorbed in tumor sites such as subcutaneous tumors and in situ brain gliomas, and can pass through the blood-brain barrier to be enriched in brain gliomas. The T / N ratio is as low as 7:1 (Table 2) and can reach 70:1 (Table 1), which solves the defect that ordinary nano drugs cannot pass through the blood-brain barrier.
[0078] Example 6-12 Preparation of other boron-containing drugs
[0079] The preparation of Examples 6-12 refers to Example 1, and the amount of each component in Table 3 is expressed in parts by mass.
[0080] Table 3 Composition and properties of boron-containing drugs in Examples 6-12
[0081] .
[0082] When the dosage is 150 mg / kg, the boron-containing drugs prepared in Examples 6-12 have a T / N ratio between 5:1 and 70:1 in the mouse subcutaneous brain glioma model distribution experiment. Figure 7 shown.
[0083] Example 13 Photothermal Experiment of Boron-Containing Drugs
[0084] Use a semiconductor laser subsystem to emit 808nm near-infrared laser and set the laser spot area to 0.6cm 2 , add 0.1 mg / mL boron-containing drug aqueous solution of Example 1 into a quartz cuvette, and use a power density of 1.5 W / cm 2 The near-infrared excitation light source (wavelength 808nm) was irradiated for 15min, and the solution temperature was measured with a thermometer every 30s. The specific results are shown in Figure 8 The above values finally calculated that the photothermal conversion efficiency of boron-containing drugs is 39.46%.
[0085] Example 14 Photothermal therapy of subcutaneous brain glioma in mice using boron-containing drugs
[0086] Physiological saline and 150 mg / kg of the boron-containing drug of Example 1 were injected into tumor-bearing mice via the tail vein, and irradiated with a near-infrared excitation light source (wavelength of 808 nm) for 30 minutes. The volume of subcutaneous brain glioma in mice was measured on the 3rd, 5th and 10th days. The specific results are shown in Table 4.
[0087] Table 4 Volume of subcutaneous glioma in mice
[0088] .
[0089] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. However, these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A boron-containing drug, characterized in that: Obtained by polymerization of dopamine and its derivatives with boron-containing compounds; Wherein, the boron-containing compound includes any one or more of boric acid, phenylalanine borate, proline borate, tyrosine borate, 5-amino-2,3-difluorophenylboric acid, 3-amino-5-cyanophenylboric acid, 3-amino-4-methylphenylboric acid, 3-aminophenylboric acid hydrochloride, and 4-carbamoylphenylboric acid; The dopamine and its derivatives include any one or more of dopamine, norepinephrine, levomethyldopa, droxidopa, and 5-hydroxydopamine.
2. The boron-containing drug according to claim 1, characterized in that The boric acid phenylalanine is 4-boronic acid-L-phenylalanine.
3. The boron-containing drug according to claim 1, characterized in that The dopamine and its derivatives are dopamine, levomethyldopa or 5-hydroxydopamine.
4. The boron-containing drug according to claim 1, characterized in that The mass ratio of the dopamine and its derivatives to the boron-containing compound is (1-10):
1.
5. The boron-containing drug according to claim 4, characterized in that The mass ratio of the dopamine and its derivatives to the boron-containing compound is (3-4):
1.
6. The boron-containing drug according to claim 1, characterized in that The boron content in the boron-containing medicine is 0.1% to 1.0%.
7. The boron-containing drug according to any one of claims 1 to 6, characterized in that: The boron-containing drug is used for head and neck tumors, lung cancer, peritoneal cancer, gastric cancer, melanoma, pancreatic cancer, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, breast cancer, colorectal cancer, uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, vulvar cancer, B-cell lymphoma or leukemia.
8. The boron-containing drug according to claim 7, characterized in that The liver cancer is hepatocellular carcinoma.
9. The boron-containing drug according to claim 7, characterized in that The head and neck tumor is thyroid cancer.
10. The boron-containing drug according to claim 7, characterized in that The boron-containing drug is indicated for head and neck tumors, melanoma or brain glioma.
11. A method for preparing a boron-containing drug as claimed in any one of claims 1 to 10, characterized in that: The method comprises the following steps: mixing an aqueous solution of dopamine and its derivatives with an aqueous solution of a boron-containing compound for reaction, separating the solid from the liquid to obtain a solid, and washing and freeze-drying the solid.
12. The method according to claim 11, characterized in that The pH of the mixed reaction is 6-14.
13. The method according to claim 12, characterized in that The mixing reaction time is 0.5 to 48 hours, and the stirring speed during the reaction is above 200 revolutions per minute.
